Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Lipase & amylase & protease
All products: Limited Use (codes 124, 125, 126, 225)
Creon Minimicrospheres 35 · DIN 02494639 · 35000 & 35700 & 2240 Units · DR capsule
Limited Use, Reason for Use code 124, 125, 126, 225 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 124, 125, 126, 225 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 or 225 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126, 225
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 225
Replacement therapy for pancreatic insufficiency due to cystic fibrosis.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Creon Minimicrospheres 35 · DIN 02494639
Manufacturer: BGP Pharma ULC; listing date 2021-10-29
Health Canada: Marketed since 2021-01-26 · brand CREON MINIMICROSPHERES 35 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients LIPASE 35000 UNIT, AMYLASE 35700 UNIT, PROTEASE 2240 UNIT · company Bgp pharma ulc · schedule Prescription
Creon Minimicrospheres 35: Formulary list price $0.97 per unit (the source does not state the unit; exact figure $0.9741). What the ministry pays, not the patient.
Ministry pays: $0.9741 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02494639: Creon Minimicrospheres 35
Raw flags: sec12=Y, sec3=Y
Item: 561600057; group id 657; item number 1640; lccId 00348; manufacturer id BGP
Source form: DR Cap; strength: 35000 & 35700 & 2240 Units
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.9741; ministry $0.9741
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02494639
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98463
Shortage status: resolved shortage (ended September 23, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02494639
Shortage record checked October 6, 2026
Pancrelipase equivalent to lipase & amylase & protease
Form:
9 of 9 products shown
All products: Limited Use (codes 124, 125, 126, 225)
Viokace · DIN 02241933 · 16 mg · tablet
Limited Use, Reason for Use code 124, 125, 126 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 124, 125, 126 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Viokace · DIN 02241933
Manufacturer: Nestle Enterprises S.A.; listing date 2001-03-07
Health Canada: Marketed since 2020-07-02 · brand VIOKACE · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Tablet · route Oral · ingredients AMYLASE 113400 UNIT, LIPASE 20880 UNIT, PROTEASE 112500 UNIT · company Nestle enterprises s.a. · schedule Prescription
DIN 02241933: Viokace
Raw flags: sec12=Y, sec3=Y
Item: 561600034; group id 661; item number 1649; lccId 00098; manufacturer id NSA
Source form: Tab; strength: 16mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6521; ministry $0.6521
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02241933
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65603
Shortage status: resolved shortage (ended August 2, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241933
Shortage record checked October 6, 2026
Pancrease MT4 · DIN 00789445 · 4000 & 12000 & 12000 USP Units · Ent Microsph capsule
Limited Use, Reason for Use code 124, 125, 126 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 124, 125, 126 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Pancrease MT4 · DIN 00789445
Manufacturer: Vivus Inc.; listing date 1996-10-01
Health Canada: Marketed since 2019-08-01 · brand PANCREASE MT 4 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients PROTEASE 10000 UNIT, LIPASE 4200 UNIT, AMYLASE 17500 UNIT · company Vivus llc. · schedule Prescription
Pancrease MT4: Formulary list price $0.73 per unit (the source does not state the unit; exact figure $0.7274). What the ministry pays, not the patient.
Ministry pays: $0.7274 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00789445: Pancrease MT4
Raw flags: sec12=Y, sec3=Y
Item: 561600026; group id 659; item number 1644; lccId 00098; manufacturer id VIU
Source form: Ent Microsph Cap; strength: 4000 & 12000 & 12000 USP Units
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.7274; ministry $0.7274
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00789445
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9514
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00789445
Shortage record checked October 6, 2026
Creon Minimicrospheres Micro · DIN 02445158 · 5100 & 500 & 320 Units/100 mg · Gran - 100mg/Scoop
Limited Use, Reason for Use code 124, 125, 126, 225 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 124, 125, 126, 225 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 or 225 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126, 225
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 225
Replacement therapy for pancreatic insufficiency due to cystic fibrosis.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Creon Minimicrospheres Micro · DIN 02445158
Manufacturer: BGP Pharma ULC; listing date 2017-04-27
Health Canada: Marketed since 2015-11-18 · brand CREON MINIMICROSPHERES MICRO · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Granules for suspension (delayed-release · route Oral · ingredients LIPASE 5000 UNIT/100MG, AMYLASE 5100 UNIT/100MG, PROTEASE 320 UNIT/100MG · company Bgp pharma ulc · schedule Prescription
Creon Minimicrospheres Micro: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1912). What the ministry pays, not the patient.
Ministry pays: $0.1912 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02445158: Creon Minimicrospheres Micro
Raw flags: sec12=Y, sec3=Y
Item: 561600056; group id 660; item number 1647; lccId 00097; manufacturer id BGP
Source form: Gran - 100mg/Scoop; strength: 5100 & 500 & 320 Units/100mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.1912; ministry $0.1912
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02445158
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93037
Shortage status: resolved shortage (ended March 13, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02445158
Shortage record checked October 6, 2026
Cotazym ECS 8 · DIN 00502790 · 8000 & 30000 & 30000 USP Units · Ent Microsph capsule
Limited Use, Reason for Use code 124, 125, 126, 225 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 124, 125, 126, 225 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 or 225 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126, 225
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 225
Replacement therapy for pancreatic insufficiency due to cystic fibrosis.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Cotazym ECS 8 · DIN 00502790
Manufacturer: Organon Canada Ltd./Ltee; listing date 1996-10-01
Health Canada: Marketed since 2021-11-01 · brand COTAZYM ECS 8 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients LIPASE 10800 UNIT, AMYLASE 42000 UNIT, PROTEASE 45000 UNIT · company Choay lab · schedule Prescription
Cotazym ECS 8: Formulary list price $0.54 per unit (the source does not state the unit; exact figure $0.5365). What the ministry pays, not the patient.
Ministry pays: $0.5365 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00502790: Cotazym ECS 8
Raw flags: sec12=Y, sec3=Y
Item: 561600023; group id 658; item number 1642; lccId 00097; manufacturer id ORG
Source form: Ent Microsph Cap; strength: 8000 & 30000 & 30000 USP Units
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.5365; ministry $0.5365
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00502790
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3891
Shortage status: anticipated shortage (last updated June 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00502790
Shortage record checked October 6, 2026
Cotazym · DIN 00263818 · 10000 & 40000 & 35000 USP Units · capsule
Limited Use, Reason for Use code 124, 125, 126, 225 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 124, 125, 126, 225 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 or 225 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126, 225
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 225
Replacement therapy for pancreatic insufficiency due to cystic fibrosis.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Cotazym · DIN 00263818
Manufacturer: Organon Canada Ltd./Ltee; listing date 1996-10-01
Health Canada: Marketed since 2022-01-07 · brand COTAZYM · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (immediate-release) · route Oral · ingredients LIPASE 10000 UNIT, AMYLASE 40000 UNIT, PROTEASE 35000 UNIT · company Organon canada inc. · schedule Prescription
DIN 00263818: Cotazym
Raw flags: sec12=Y, sec3=Y
Item: 561600022; group id 658; item number 1641; lccId 00097; manufacturer id ORG
Source form: Cap; strength: 10000 & 40000 & 35000 USP Units
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2972; ministry $0.2972
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00263818
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1649
Shortage status: active shortage (reported September 22, 2026, estimated to end February 28, 2027, last updated September 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00263818
Shortage record checked October 6, 2026
Creon 10 · DIN 02200104 · 10000 & 33200 & 37500 USP Units · Ent Minimicrosph capsule
Limited Use, Reason for Use code 124, 125, 126, 225 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 124, 125, 126, 225 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 or 225 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126, 225
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 225
Replacement therapy for pancreatic insufficiency due to cystic fibrosis.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Creon 10 · DIN 02200104
Manufacturer: Solvay Pharma Inc.; listing date 1998-12-31
Health Canada: Marketed since 2015-11-20 · brand CREON MINIMICROSPHERES 10 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients AMYLASE 11200 UNIT, PROTEASE 730 UNIT, LIPASE 10000 UNIT · company Bgp pharma ulc · schedule Prescription
DIN 02200104: Creon 10
Raw flags: sec12=Y, sec3=Y
Item: 561600030; group id 660; item number 1645; lccId 00097; manufacturer id SPH
Source form: Ent Minimicrosph Cap; strength: 10000 & 33200 & 37500 USP Units
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2954; ministry $0.2954
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02200104
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36179
Shortage status: resolved shortage (ended December 13, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02200104
Shortage record checked October 6, 2026
Viokace · DIN 02230019 · 10440 & 56400 & 57100 USP Units · tablet
Limited Use, Reason for Use code 124, 125, 126 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 124, 125, 126 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Viokace · DIN 02230019
Manufacturer: Nestle Enterprises S.A.; listing date 1997-03-14
Health Canada: Marketed since 2020-07-02 · brand VIOKACE · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Tablet · route Oral · ingredients PROTEASE 57100 UNIT, AMYLASE 56400 UNIT, LIPASE 10440 UNIT · company Nestle enterprises s.a. · schedule Prescription
DIN 02230019: Viokace
Raw flags: sec12=Y, sec3=Y
Item: 561600029; group id 661; item number 1648; lccId 00098; manufacturer id NSA
Source form: Tab; strength: 10440 & 56400 & 57100 USP Units
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4249; ministry $0.4249
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02230019
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=48551
Shortage status: resolved shortage (ended October 6, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02230019
Shortage record checked October 6, 2026
Cotazym ECS 20 · DIN 00821373 · 20000 & 55000 & 55000 USP Units · Ent Microsph capsule
Limited Use, Reason for Use code 124, 125, 126, 225 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 124, 125, 126, 225 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 or 225 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126, 225
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 225
Replacement therapy for pancreatic insufficiency due to cystic fibrosis.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Cotazym ECS 20 · DIN 00821373
Manufacturer: Organon Canada Ltd./Ltee; listing date 1997-04-10
Health Canada: Marketed since 2021-12-17 · brand COTAZYM ECS 20 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients LIPASE 25000 UNIT, AMYLASE 100000 UNIT, PROTEASE 100000 UNIT · company Organon canada inc. · schedule Prescription
Cotazym ECS 20: Formulary list price $1.41 per unit (the source does not state the unit; exact figure $1.4067). What the ministry pays, not the patient.
Ministry pays: $1.4067 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00821373: Cotazym ECS 20
Raw flags: sec12=Y, sec3=Y
Item: 561600014; group id 658; item number 1643; lccId 00097; manufacturer id ORG
Source form: Ent Microsph Cap; strength: 20000 & 55000 & 55000 USP Units
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.4067; ministry $1.4067
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00821373
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9892
Shortage status: anticipated shortage (last updated June 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00821373
Shortage record checked October 6, 2026
Creon 25 · DIN 01985205 · 25000 & 74000 & 62500 USP Units · Ent Minimicrosph capsule
Limited Use, Reason for Use code 124, 125, 126, 225 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 124, 125, 126, 225 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 or 225 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 124, 125, 126, 225
Reason for Use code 124
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 125
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 126
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 225
Replacement therapy for pancreatic insufficiency due to cystic fibrosis.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Creon 25 · DIN 01985205
Manufacturer: Solvay Pharma Inc.; listing date 1996-10-01
Health Canada: Marketed since 2015-11-20 · brand CREON MINIMICROSPHERES 25 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients AMYLASE 25500 UNIT, PROTEASE 1600 UNIT, LIPASE 25000 UNIT · company Bgp pharma ulc · schedule Prescription
DIN 01985205: Creon 25
Raw flags: sec12=Y, sec3=Y
Item: 561600025; group id 660; item number 1646; lccId 00097; manufacturer id SPH
Source form: Ent Minimicrosph Cap; strength: 25000 & 74000 & 62500 USP Units
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.9229; ministry $0.9229
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01985205
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13302
Shortage status: active shortage (reported September 21, 2026, estimated to end November 10, 2026, last updated September 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01985205
Shortage record checked October 6, 2026
Other drugs in the same formulary class (56:16 Digestants) and how they are covered
No products matched this class search: “56:16”.
This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code.
Search this as a medication name or DIN
1 INDICATIONS
CREON MINIMICROSPHERES® (pancreatin) is indicated in pediatric and adult patients for:
• treatment of pancreatic exocrine insufficiency (PEI) attributed to cystic fibrosis, chronic
pancreatitis, or any other medically defined pancreatic disease that might require
pancreatic enzyme therapy
including, but not limited to:
• cystic fibrosis
• chronic pancreatitis
• pancreatic surgery
• gastrectomy
• pancreatic cancer
• gastrointestinal bypass surgery (e.g. Billroth II gastroenterostomy)
• ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)
• Shwachman-Diamond Syndrome
• status after an attack of acute pancreatitis and initiation of enteral or oral feeding
1.1 Pediatrics (≤ 18 years of age)
CREON MINIMICROSPHERES® was shown to be effective in pediatric populations with
PEI due to cystic fibrosis, independent of age and severity of the disease. The efficacy
and safety observed during CREON MINIMICROSPHERES® treatment in these patients
was similar to that in adult patients (See 8 ADVERSE REACTIONS and 14 CLINICAL
TRIALS).
1.2 Geriatrics (≥ 6…
https://pdf.hres.ca/dpd_pm/00076423.PDF
PM date: November 25, 2013
Source product: CREON MINIMICROSPHERES 35; DIN 02494639; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
COTAZYM® (pancreatic enzymes) is indicated for the treatment of pancreatic insufficiency
attributed to cystic fibrosis, chronic pancreatitis, or any other medically defined pancreatic disease
that might require pancreatic enzyme therapy.
Geriatrics (> 65 years of age):
Clinical studies of COTAZYM® in geriatric patients have not been conducted.
Pediatrics (<18 years of age):
Post approval, several clinical studies have been conducted supporting the safe and effective use
of COTAZYM® in pediatric patients with established pancreatic insufficiency.
https://pdf.hres.ca/dpd_pm/00060547.PDF
PM date: March 30, 2021
Source product: COTAZYM; DIN 00263818; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Cotazym · DIN 00263818
Shortage status: active shortage (reported 2026-09-22, estimated to end 2027-02-28, last updated 2026-09-25); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00263818
Creon 25 · DIN 01985205
Shortage status: active shortage (reported 2026-09-21, estimated to end 2026-11-10, last updated 2026-09-29); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01985205